| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 10/28/2004 | WO2003086298A3 Use of interleukin-19 to treat ovarian cancer |
| 10/28/2004 | WO2003077840A3 Method of modulating inflammatory response |
| 10/28/2004 | WO2003076490A8 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound |
| 10/28/2004 | WO2003030833A3 Angiopoietin-2 specific binding agents |
| 10/28/2004 | WO2003020954A3 205p1b5 in treatment and detection of cancer |
| 10/28/2004 | WO2001081540A3 Growth factor which acts through erb b-4 rtk |
| 10/28/2004 | US20040215292 Photodynamic treatment of targeted cells |
| 10/28/2004 | US20040215019 Substituted isoindoles and the e use thereof |
| 10/28/2004 | US20040215018 use as selective estrogen receptor modulators, and use in inhibiting bone loss, cardiovascular disease, and breast and uterine carcinoma |
| 10/28/2004 | US20040215017 Such as 2-methylpropyl-(4-bromo-3-fluorophenyl)carbamate |
| 10/28/2004 | US20040214996 Multimeric peptides/immunoglobulins for use in the treatment of bone disorders |
| 10/28/2004 | US20040214995 Melanoma antigens and their use in diagnostic and therapeutic methods |
| 10/28/2004 | US20040214990 Transmembrane protein differentially expressed in cancer |
| 10/28/2004 | US20040214928 For therapy of proliferative disorders and neurological disorders |
| 10/28/2004 | US20040214902 Small molecule antagonists of BCL-2 family proteins |
| 10/28/2004 | US20040214896 drugs and/or prodrugs such as N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide, used for prophylaxis of inflammatory disorders, cancers, psoriasis, diabetes, autoimmune diseases, hepatitis, graft versus host disease or endometriosis |
| 10/28/2004 | US20040214888 Carboxylic acid derivative and medicine comprising salt or ester of the same |
| 10/28/2004 | US20040214880 Antitumor agents, anticarcinogenic agents; inhibitors of histone deacetylase; a methyleneaminooxymethyl)-thiophene-2-carboxylic acid (2-amino-phenyl)-amide derivatives; chemical synthesis |
| 10/28/2004 | US20040214876 Tetramerous derivative of indole-3-carbinol with anti-carcinogenic activity and method of synthesis of said derivative |
| 10/28/2004 | US20040214874 Inhibition of protein-tyrosine kinase cmet to block cancer cell proliferation, oral bioavailibility; 2-(2,6-dichlorophenyl)-4-phenyl-5-(pyrimidin-4yl)-1H-imidazoles |
| 10/28/2004 | US20040214871 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester |
| 10/28/2004 | US20040214864 Novel compounds |
| 10/28/2004 | US20040214862 A N'-hydroxy-terephthalamide derivatives; histone deacetylase enzyme inhibitors; ANTIPROLIFERATIVE AGENTS; ANTITUMOR AGENTS |
| 10/28/2004 | US20040214850 Useful against multidrug resistant cancer cells |
| 10/28/2004 | US20040214843 Such as spiro(cyclohexane-1-4'-(3',4'-dihydro)quinazolin)-2'(1'H)-one for treatment of T-cell-related diseases, autoimmune diseases, osteoarthritis, multiple sclerosis, osteoporosis, asthma and cancer |
| 10/28/2004 | US20040214841 Quinazoline derivatives for treatment of tumours |
| 10/28/2004 | US20040214830 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors |
| 10/28/2004 | US20040214822 Substituted 4-aminocyclohexanol compounds |
| 10/28/2004 | US20040214821 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| 10/28/2004 | US20040214820 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 10/28/2004 | US20040214814 Pyrazole compounds useful as protein kinase inhibitors |
| 10/28/2004 | US20040214799 for suppression of cancer cell invasion and cancer metastasis |
| 10/28/2004 | US20040214784 covalent conjugates with mono-, di- , poly- or thiaalkanoic acids; ability to adjust the solubility of steroidal molecules, lipophilicity and bioavailability by altering the structure and length of the acid chain; avoids or reduces the local irritation caused by the parent drug |
| 10/28/2004 | US20040214765 Methods and means for inhibition of CDK4 activity |
| 10/28/2004 | US20040214761 induction of apoptosis in tumor cells by administering monoclonal antibodies |
| 10/28/2004 | US20040214759 Compositions and methods of use for a fibroblast growth factor |
| 10/28/2004 | US20040214755 cyclic depsipeptides and/or mimetics, used as anticarcinogenic agents, formed by cyclization of polypeptides |
| 10/28/2004 | US20040214331 Transforming and propagating viral-like particle in cells; for use as tools in prevention and treatment of viral infection; viricides and genetic vaccines |
| 10/28/2004 | US20040214286 Comprises nucleotide sequences coding cell growth factors for use in developing modulators for treatment of cell proliferative, arthritic, skin and vision defects; immunotherapy |
| 10/28/2004 | US20040214247 Comprises immunoglobulin which binds to tumor specific epitope and inhibits binding of matrix protein/collagen/gelatin complexes; immunotherapy and antitumor agents |
| 10/28/2004 | US20040214245 Diagnostic and therapeutic use of antibodies against the urokinase receptor |
| 10/28/2004 | US20040214190 Mammalian c-type lectins |
| 10/28/2004 | US20040214158 Treatment of human papillomavirus (hpv)-infected cells |
| 10/28/2004 | US20040213833 certain MMP inhibitory peptides improve the targeting of liposomes to cancer cells and enhance the uptake thereof by such cells |
| 10/28/2004 | US20040213799 Boosting priming composition with nonreplicating and/or replication impaired strains of poxvirus vectors; forming human immunodeficiency virus inhibitors |
| 10/28/2004 | US20040213797 Conjugates for the modulation of immune responses |
| 10/28/2004 | US20040213796 Immunotherapy for chronic myelocytic leukemia |
| 10/28/2004 | US20040213793 nucleic acid molecule encoding a transmembrane TEM1; Inhibiting neoangiogenesis by administering a molecule with an antibody variable region which specifically binds to an extracellular domain of a Tumor Endothelial Markers (TEMs) protein; polycystic kidney disease; psoriasis |
| 10/28/2004 | US20040213791 Monoclonal antibodies; for diagnosis and treatment of prostate cell proliferative disorders; immunogens; immunotherapy; cell lines |
| 10/28/2004 | US20040213784 bone marrow transplant (BMT), peripheral blood stem cell (PBSC); use of anti-CD20 monoclonal antibody (RITUXAN) as a purging agent during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias; enhance engraftment and/or prevent disease relapse |
| 10/28/2004 | US20040213737 Radioactive arsenic-containing compounds and their uses in the treatment of tumors |
| 10/28/2004 | US20040211940 Plasminogen Activator Assay Involving an Elastase Inhibitor |
| 10/28/2004 | CA2548643A1 System capable of treating and defining various diseases using stem cells |
| 10/28/2004 | CA2522595A1 Compositions useful as inhibitors of protein kinases |
| 10/28/2004 | CA2522266A1 Phenylazole compound, production process therefor and antioxidant |
| 10/28/2004 | CA2522203A1 Identification of n-alkylglycine trimers for induction of apoptosis |
| 10/28/2004 | CA2522076A1 Method for identifying modulators of g protein coupled receptor signaling |
| 10/28/2004 | CA2521965A1 Somatostatin-dopamine chimeric analogs |
| 10/28/2004 | CA2521842A1 Phosphate derivatives of pharmaceutical products |
| 10/28/2004 | CA2521841A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders |
| 10/28/2004 | CA2521812A1 Optimal polyvalent vaccine for cancer |
| 10/28/2004 | CA2521809A1 Improved heat shock protein-based vaccines and immunotherapies |
| 10/28/2004 | CA2463487A1 Tumours treating combinations, compositions and methods |
| 10/28/2004 | CA2463464A1 Methods of treatment and compositions therefor |
| 10/27/2004 | EP1471147A2 Method of making a recombinant molecule for the expression of HPV-16 L1 protein |
| 10/27/2004 | EP1471146A2 A packaging cell line expressing for use in facilitating the development of high capacity adenoviral vectors |
| 10/27/2004 | EP1471063A1 Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| 10/27/2004 | EP1471056A1 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 10/27/2004 | EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| 10/27/2004 | EP1471052A1 Geranyl compounds |
| 10/27/2004 | EP1471049A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| 10/27/2004 | EP1470821A2 Cell therapy method for the treatment of tumours |
| 10/27/2004 | EP1470817A1 Compositions for preventing human cancer and method of preventing human cancer |
| 10/27/2004 | EP1470257A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470256A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE /GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470246A2 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
| 10/27/2004 | EP1470239A2 Psoriasin expression by breast epithelial cells |
| 10/27/2004 | EP1470231A2 Methods of obtaining isoform specific expression in mammalian cells |
| 10/27/2004 | EP1470218A2 Corona-virus-like particles comprising functionally deleted genomes |
| 10/27/2004 | EP1470161A1 Bispecific antibody dna constructs for intramuscular administration |
| 10/27/2004 | EP1470159A2 Antibody to latent membrane proteins and uses thereof |
| 10/27/2004 | EP1470155A2 Pluripotency determining factors and uses thereof |
| 10/27/2004 | EP1470150A2 Corticosteroids nitrate derivatives |
| 10/27/2004 | EP1470148A2 Double-stranded oligonucleotides |
| 10/27/2004 | EP1470146A2 Antibodies against the muc18 antigen |
| 10/27/2004 | EP1470144A2 Oligonucleotides comprising alternating segments and uses thereof |
| 10/27/2004 | EP1470143A1 Compounds that inhibit factor xa activity |
| 10/27/2004 | EP1470139A2 NOVEL, WATER−SOLUBLE PORPHYRIN PLATINUM COMPOUNDS WITH HIGH TUMOR SELECTIVITY AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOR DISEASES |
| 10/27/2004 | EP1470138A1 Mmp inhibitors |
| 10/27/2004 | EP1470137A1 Edg receptor agonists |
| 10/27/2004 | EP1470127A1 N, n'-dimethylated n-confused porphyrins |
| 10/27/2004 | EP1470124A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES |
| 10/27/2004 | EP1470122A1 Rho-kinase inhibitors |
| 10/27/2004 | EP1470121A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 10/27/2004 | EP1470120A1 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives |
| 10/27/2004 | EP1470112A1 Substituted pyridazinones as inhibitors of p38 |
| 10/27/2004 | EP1470104A2 Novel compounds that inhibit factor xa activity |
| 10/27/2004 | EP1469887A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 10/27/2004 | EP1469882A2 Treatment of ms with goat serum |
| 10/27/2004 | EP1469878A2 Fgfr agonists |